Skip to content

A Study to Evaluate the Efficacy of Supplementation with Bacillus Coagulans SNZ 1969 In Reducing Infection in Malnourished Children and To Evaluate Its Safety

A Randomized, Double Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy of Supplementation with Bacillus Coagulans SNZ 1969 In Reducing Infection in Malnourished Children and To Evaluate Its Safety

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/031870
Enrollment
80
Registered
2021-03-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E40-E46- Malnutrition

Interventions

Intervention1: SPORLAC SYRUP: ARM A will receive syrup which contain 300 million CFU of bacillus coagulans per 5ml TDS in double blind randomized fashion for a duration of 3 months. Control Interventi

Sponsors

Madeline J Fernandes
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age 1-5years 2.Evidence of moderate malnutrition (having a weight-for-height z-score of -3.0 to less than -2.0)

Exclusion criteria

Exclusion criteria: 1.Age 5yrs, 2.History suggestive of Chronic inflammatory bowel diseases, 3.Immunocompromised /HIV positive. 4.Any evidence of Malignancy. 5.History and clinical findings suggestive of Metabolic diseases 6.History and clinical findings suggestive of Chronic respiratory tract diseases including respiratory allergies and cystic fibrosis. 7.Malformations of gastrointestinal or urinary or respiratory tract on clinical or radiological findings. 8.History of respiratory or gastrointestinal or urinary tract surgery. 9.History and Clinical findings suggestive of Congenital cardiac defects. 10.History suggestive of challenge-proved food allergy and Food intolerance. 11.Normal nourished (-1 12.History of use of antibiotics or pre/pro/symbiotic or immune stimulating products in the 2 weeks before the enrolment.

Design outcomes

Primary

MeasureTime frame
Number of episodes of gastrointestinal or respiratory tract infections during the period from day 0 to day 90Timepoint: Number of episodes of gastrointestinal or respiratory tract infections during the period from day 0 to day 90

Secondary

MeasureTime frame
Emergency Department Medical visit if child has symptoms of gastrointestinal and respiratory tract infectionTimepoint: day o to day 90;Number of children experiencing at least one episode of AGI or RTI in 30 daysTimepoint: day 0 to day 90;Number of children experiencing at least one episode of AGI or RTI in 60 daysTimepoint: day 0 to day 90;Number of children experiencing at least one episode of AGI or RTI in 90 daysTimepoint: day 0 to day 90;Number of children with diarrheal episodesTimepoint: day 0 to day 90;Number of children with lower respiratory tract infections, including pneumonia, bronchitis, and bronchiolitisTimepoint: day o to day 90;Number of children with upper respiratory tract infection, including rhinitis, pharyngitis, sinusitis, otitis, and the common coldTimepoint: day 0 to day 90;Number of children with vomiting episodesTimepoint: day 0 to day 90;Number of days of preschool lost by childrenTimepoint: day o to day 90;Number of days of work lost by the parentsTimepoint: day 0 to day 90;Number of gastrointestinal infections lasting longer than 2 daysTimepoint: day 0 to day 90;Number of respiratory tract infections lasting longer than 3 days.Timepoint: day 0 to day 90;Number of severe diarrhea episodes.Timepoint: day o to day 90;Total days of illnessTimepoint: day 0 to day 90;Total Number of Days with respiratory and gastrointestinal SymptomsTimepoint: day o to day 90

Countries

India

Contacts

Public ContactMadeline Janice Fernandes

Byramjee jheejheeboy government medical college

daswani_bharti@rediffmail.com9421965337

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026